Jürgen Finke focuses on Transplantation, Internal medicine, Surgery, Gastroenterology and Hematopoietic stem cell transplantation. His studies in Transplantation integrate themes in fields like Haematopoiesis, Survival analysis, Immunology and Hazard ratio. His Internal medicine study deals with Oncology intersecting with Risk factor and Donor lymphocyte infusion.
His Surgery study frequently draws parallels with other fields, such as Cumulative incidence. His Gastroenterology research is multidisciplinary, relying on both Lomustine, Methotrexate, Neutropenia, Procarbazine and Acute lymphocytic leukemia. His studies deal with areas such as Clinical trial, Targeted therapy, Cytopenia, Caspase 1 and Transplantation Conditioning as well as Hematopoietic stem cell transplantation.
Jürgen Finke mainly focuses on Internal medicine, Transplantation, Surgery, Hematopoietic stem cell transplantation and Oncology. His work on Internal medicine is being expanded to include thematically relevant topics such as Gastroenterology. His Transplantation research is multidisciplinary, incorporating elements of Leukemia, Myeloid leukemia, Immunology and Stem cell.
Jürgen Finke combines topics linked to Incidence with his work on Surgery. The study incorporates disciplines such as Cancer, Regimen, Myelodysplastic syndromes, Transplantation Conditioning and Survival analysis in addition to Hematopoietic stem cell transplantation. His Oncology research incorporates themes from Chronic lymphocytic leukemia and Lymphoma.
His primary areas of study are Internal medicine, Transplantation, Oncology, Hematopoietic stem cell transplantation and Stem cell. His study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology. Jürgen Finke studies Graft-versus-host disease which is a part of Transplantation.
His work in Oncology addresses subjects such as Cohort, which are connected to disciplines such as Myelofibrosis. In his research on the topic of Hematopoietic stem cell transplantation, Transplantation Conditioning is strongly related with Myelodysplastic syndromes. His Stem cell research includes themes of Hematology and Immunology.
His scientific interests lie mostly in Transplantation, Internal medicine, Hematopoietic stem cell transplantation, Oncology and Leukemia. His research integrates issues of Myeloid leukemia, Stem cell, Bone marrow and Disease in his study of Transplantation. His work in Bone marrow covers topics such as Gastroenterology which are related to areas like Incidence.
Within one scientific family, Jürgen Finke focuses on topics pertaining to Surgery under Internal medicine, and may sometimes address concerns connected to Confidence interval. Jürgen Finke interconnects Survival rate, Myelofibrosis, Transplantation Conditioning and Myelodysplastic syndromes in the investigation of issues within Hematopoietic stem cell transplantation. While the research belongs to areas of Leukemia, Jürgen Finke spends his time largely on the problem of Myeloid, intersecting his research to questions surrounding Cyclophosphamide, T cell, Antigen presentation and Janus kinase 2.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia
Vanderson Rocha;Myriam Labopin;Guillermo Sanz;William Arcese.
The New England Journal of Medicine (2004)
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial
Jürgen Finke;Wolfgang A Bethge;Claudia Schmoor;Hellmut D Ottinger.
Lancet Oncology (2009)
Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
M. Aoudjhane;M. Labopin;N. C. Gorin;A. Shimoni.
Donor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
Christoph Schmid;Myriam Labopin;Arnon Nagler;Martin Bornhäuser.
Journal of Clinical Oncology (2007)
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.
Rodrigo Martino;Simona Iacobelli;Ronald Brand;Thekla Jansen.
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
R.M. Weber-Nordt;C. Egen;J. Wehinger;W.D. Ludwig.
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
R. Zeiser;A. Burchert;C. Lengerke;M.M. Verbeek.
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
Pierre Reusser;Hermann Einsele;John Lee;Liisa Volin.
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer;Thorsten Zenz;Dirk Winkler;Andreas Bühler.
Journal of Clinical Oncology (2009)
Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R
Konrad Wilhelm;Jayanthi Ganesan;Tobias Müller;Christoph Dürr.
Nature Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: